American Journal of Kidney Diseases
Volume 49, Issue 1 , Pages 118-126 , January 2007

C-Reactive Protein Haplotype Predicts Serum C-Reactive Protein Levels But Not Cardiovascular Disease Risk in a Dialysis Cohort

Received 30 May 2006 ,Accepted 10 October 2006.

References 

  1. Danesh J, Wheeler JG, Hirschfield GM, et al. C-Reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1397
  2. Fortmann SP, Ford E, Criqui MH, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to clinical and public health practice: Report from the population science discussion group. Circulation. 2004;110:e554–e559
  3. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35:469–476
  4. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648–658
  5. Kaysen GA. The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol. 2001;12:1549–1557
  6. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol. 2002;13:1918–1927
  7. Peppa M, Uribarri J, Cai W, Lu M, Vlassara H. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis. 2004;43:690–695
  8. Davey SG, Ebrahim S. ‘Mendelian randomization’: Can genetic epidemiology contribute to understanding environmental determinants of disease?. Int J Epidemiol. 2003;32:1–22
  9. Best LG, North KE, Tracy RP, et al. Genetic determination of acute phase reactant levels: The Strong Heart Study. Hum Hered. 2004;58:112–116
  10. Dupuis J, Larson MG, Vasan RS, et al. Genome scan of systemic biomarkers of vascular inflammation in the Framingham Heart Study: Evidence for susceptibility loci on 1q. Atherosclerosis. 2005;182:307–314
  11. Kovacs A, Green F, Hansson LO, et al. A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis. 2005;178:193–198
  12. Suk HJ, Ridker PM, Cook NR, Zee RY. Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis. 2005;178:139–145
  13. Szalai AJ, Wu J, Lange EM, et al. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med. 2005;83:440–447
  14. Carlson CS, Aldred SF, Lee PK, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet. 2005;77:64–77
  15. Zee RY, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis. 2002;162:217–219
  16. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun. 2002;3:14–19
  17. Kaysen GA, Dubin JA, Muller HG, Rosales LM, Levin NW The HEMO Study Group. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. Kidney Int. 2000;58:346–352
  18. Powe NR, Klag MJ, Sadler JH, et al. Choices for Healthy Outcomes in Caring for End Stage Renal Disease. Semin Dial. 1996;9–11
  19. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet. 2004;74:106–120
  20. Smith MW, Patterson N, Lautenberger JA, et al. A high-density admixture map for disease gene discovery in African Americans. Am J Hum Genet. 2004;74:1001–1013
  21. Patterson N, Hattangadi N, Lane B, et al. Methods for high-density admixture mapping of disease genes. Am J Hum Genet. 2004;74:979–1000
  22. Lake SL, Lyon H, Tantisira K, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered. 2003;55:56–65
  23. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002;70:425–434
  24. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978–989
  25. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003;73:1162–1169
  26. Miller DT, Zee RY, Suk DJ, et al. Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet. 2005;69:623–638
  27. Timpson NJ, Lawlor DA, Harbord RM, et al. C-Reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet. 2005;366:1954–1959
  28. Parekh RS, Zhang L, Fivush BA, Klag MJ. Incidence of atherosclerosis by race in the dialysis morbidity and mortality study: A sample of the US ESRD population. J Am Soc Nephrol. 2005;16:1420–1426
  29. Zee RY, Hegener HH, Fernandez-Cruz A, Lindpaintner K. C-Reactive protein gene polymorphisms and the incidence of post-angioplasty restenosis. Atherosclerosis. 2004;176:393–396
  30. Zee RY, Hegener HH, Cook NR, Ridker PM. C-Reactive protein gene polymorphisms and the risk of venous thromboembolism: A haplotype-based analysis. J Thromb Haemost. 2004;2:1240–1243
  31. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2000;29:722–729

 Support: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study is supported by grant no. RO1-HL-62985 from the National Heart, Lung, and Blood Institute; grant no. RO1-DK-59616 from the National Institute of Diabetes and Digestive and Kidney Diseases; grant no. R01-HS-08365 from the Agency for Healthcare Research and Quality; and a Baxter Healthcare Corporation extramural grant. J.C. is supported in part as an American Heart Association established investigator (01-4019-7N). This project has been funded in whole or part with federal funds from the National Cancer Institute, National Institutes of Health (NIH), under contract N01-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. Potential conflicts of interest: None.

PII: S0272-6386(06)01609-X

doi: 10.1053/j.ajkd.2006.10.008

American Journal of Kidney Diseases
Volume 49, Issue 1 , Pages 118-126 , January 2007

Article Tools